Your browser doesn't support javascript.
Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England.
Ladhani, Shamez N; Ireland, Georgina; Baawuah, Frances; Beckmann, Joanne; Okike, Ifeanyichukwu O; Ahmad, Shazaad; Garstang, Joanna; Brent, Andrew J; Brent, Bernadette; Aiano, Felicity; Amin-Chowdhury, Zahin; Kall, Meaghan; Borrow, Ray; Linley, Ezra; Zambon, Maria; Poh, John; Warrener, Lenesha; Lackenby, Angie; Ellis, Joanna; Amirthalingam, Gayatri; Brown, Kevin E; Ramsay, Mary E.
  • Ladhani SN; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom; Paediatric Infectious Diseases Research Group, St. George's University of London, London SW17 0RE, United Kingdom.
  • Ireland G; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Baawuah F; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Beckmann J; East London NHS Foundation Trust, 9 Alie Street, London E1 8DE, United Kingdom.
  • Okike IO; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom; University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK, 201 London Road, Derby DE1 2TZ, United Kingdom.
  • Ahmad S; Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, United Kingdom.
  • Garstang J; Birmingham Community Healthcare NHS Trust, Holt Street, Aston B7 4BN, United Kingdom.
  • Brent AJ; Nuffield Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE, United Kingdom; University of Oxford, Wellington Square, Oxford OX1 2JD, United Kingdom.
  • Brent B; Nuffield Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE, United Kingdom.
  • Aiano F; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Amin-Chowdhury Z; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Kall M; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Borrow R; Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
  • Linley E; Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom.
  • Zambon M; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Poh J; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Warrener L; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Lackenby A; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Ellis J; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Amirthalingam G; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Brown KE; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
  • Ramsay ME; Immunisation and Countermeasures Division, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.
J Infect ; 83(5): 573-580, 2021 11.
Article in English | MEDLINE | ID: covidwho-1527750
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

OBJECTIVES:

We assessed SARS-CoV-2 infection, seroprevalence and seroconversion in students and staff when secondary schools reopened in March 2021.

METHODS:

We initiated SARS-CoV-2 surveillance in 18 secondary schools across six regions in September 2020. Participants provided nasal swabs for RT-PCR and blood samples for SARS-CoV-2 antibodies at the beginning (September 2020) and end (December 2020) of the autumn term and at the start of the spring term (March 2021).

FINDINGS:

In March 2021, 1895 participants (1100 students795 staff) were tested; 5.6% (61/1094) students and 4.4% (35/792) staff had laboratory-confirmed SARS-CoV-2 infection from December 2020-March 2021. Nucleoprotein-antibody seroprevalence was 36.3% (370/1018) in students and 31.9% (245/769) in staff, while spike-antibody prevalence was 39.5% (402/1018) and 59.8% (459/769), respectively, similar to regional community seroprevalence. Between December 2020 and March 2021, 14.8% (97/656; 95%CI 12.2-17.7) students and 10.0% (59/590; 95%CI 7.7-12.7) staff seroconverted. Weekly seroconversion rates were similar from September to December 2020 (8.0/1000) and from December 2020 to March 2021 (7.9/1000; students 9.3/1,000; staff 6.3/1,000).

INTERPRETATION:

By March 2021, a third of secondary school students and staff had evidence of prior infection based on N-antibody seropositivity, and an additional third of staff had evidence of vaccine-induced immunity based on S-antibody seropositivity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Risk factors / Screening study Limits: Humans Language: English Journal: J Infect Year: 2021 Document Type: Article Affiliation country: J.jinf.2021.08.019

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Risk factors / Screening study Limits: Humans Language: English Journal: J Infect Year: 2021 Document Type: Article Affiliation country: J.jinf.2021.08.019